Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Ms. Andrea N. Flynn Ph.D.

Vice President & Head of Investor Relations

Ms. Heidi  Manna

Executive Vice President & Chief People Officer

Dr. George Christopher Eliades Ph.D.

Senior Vice President of Corporate Development & Chief Transformation Officer

Ms. Patricia  Carr

Senior Vice President & Chief Accounting Officer

Mr. Philip L. Johnson

Executive Vice President & Chief Financial Officer

Mr. Daniel N. Swisher Jr.

Non-Executive Employee

Ms. Reneé D. Galá

President & Chief Operating Officer

Ms. Neena M. Patil J.D.

Executive Vice President & Chief Legal Officer

Mr. Bruce C. Cozadd

Co-Founder, Chairman & Chief Executive Officer

Dr. Robert  Iannone M.D.

Executive Vice President and Global Head of Research & Development

Биотехнологии

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc Структура на управлението

Информация за управлението